Department of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Boston, Massachusetts.
Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore.
Semin Respir Crit Care Med. 2019 Jun;40(3):375-385. doi: 10.1055/s-0039-1693997. Epub 2019 Sep 16.
Symptomatic pleural disease, specifically malignant pleural effusion, refractory benign pleural effusion, and pneumothoraces are common diseases that often require therapeutic interventions. The spectrum of management strategies often includes selection of a chemical pleurodesis agent administered in combination with an indwelling pleural catheter or chest tube.Additionally, there is a role for minimally invasive techniques which include medical thoracoscopy or more advanced video-assisted thoracoscopic approaches. Ongoing clinical trials continue to evolve best practices regarding the optimal sclerosant agents and procedural approaches in the management of these diseases.
症状性胸腔疾病,特别是恶性胸腔积液、难治性良性胸腔积液和气胸,是常见的疾病,通常需要治疗干预。管理策略的范围通常包括选择化学胸膜固定剂,与留置性胸腔导管或胸管联合使用。此外,还有微创技术的作用,包括内科胸腔镜检查或更先进的视频辅助胸腔镜方法。正在进行的临床试验继续发展关于这些疾病管理中最佳硬化剂和程序方法的最佳实践。